MoonLake Immunotherapeutics
MLTX
111 hedge funds and large institutions have $2.67B invested in MoonLake Immunotherapeutics in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 39 reducing their positions, and 23 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
8% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 39
2.57% less ownership
Funds ownership: 99.3% → 96.73% (-2.6%)
3% less funds holding
Funds holding: 114 → 111 (-3)
11% less capital invested
Capital invested by funds: $2.99B → $2.67B (-$315M)
24% less call options, than puts
Call options by funds: $5.49M | Put options by funds: $7.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$46.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$31.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$24.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$55M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.5M |
| 4 |
PA
Perceptive Advisors
New York
|
-$17M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$7.62M |
MLTX Hedge Fund Activity: Q2 2024 in Review
111 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2024, worth a combined $2.67B — down 11% from $2.99B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MLTX and 22 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 36 added.
The largest buyer was Goldman Sachs, adding an estimated $46.3M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $55M sold.
- 111 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2024, down from 114 in Q1 2024.
- Funds reported $2.67B of MoonLake Immunotherapeutics stock for Q2 2024, down 11% quarter-over-quarter.
- 22 funds opened new MoonLake Immunotherapeutics positions in Q2 2024 and 23 closed out, a net change of -1 holder.
- The largest MoonLake Immunotherapeutics buyer in Q2 2024 was Goldman Sachs, an estimated $46.3M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $55M sold.
Based on aggregated 13F filings for Q2 2024.